The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer.

The critical components of this award mechanism are:
Impact:
Research supported by the Breakthrough Award will have the potential for a major

credit:

impact and accelerate progress toward ending breast cancer.

The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.

Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.

Research Scope:
The Breakthrough Award is structured with four different funding levels.

The levels are designed to support major (but not all) stages of research that will lead to clinical application.

Each level has a defined research scope.

It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research.

The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.

The current Program Announcement discusses the Breakthrough Award Level 3.

Funding Levels 1, 2, and 4 are available under other Program Announcements (W81XWH-20-BCRP- BTA12-2 for Levels 1 and 2 and W81XWH-20-BCRP-BTA4-2 for Level 4).

The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award Program Announcements before submitting the pre- application.

An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current Program Announcement:
Funding Level 3:
Advanced translational studies with a high degree of project readiness.

Where relevant, proof of availability of and access to necessary data, human samples, cohort(s) and/or critical reagents must be provided.

If the proposed research would ultimately require U.

S.

Food and Drug Administration (FDA) involvement, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s).

Applications must state a realistic timeline for near-term clinical investigation.

Small-scale clinical trials (e.g., first in human, Phase I/Ib) may be appropriate.

Partnering PI Option:
The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators.

The Partnering PI Option is structured to accommodate two PIs.

One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission.

The other PI will be identified as a Partnering PI.

Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components.

The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application.

New collaborations are encouraged, but not required.

The application is expected to describe how the PIs’ combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts.

To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 3 applications unless they are clearly addressing distinct research questions.

If recommended for funding, each PI will be named to an individual award within the recipient organization.

For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

Personnel:
Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.

Consumer Advocates:
Applications are required to include consumer advocate involvement.

The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project.

Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project.

Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings.

As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization.

Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application.

Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer.

The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background or training in breast cancer research to contribute to the project.